Congress wants Vytorin ad info

Share this article:

Reps. John Dingell and Bart Stupak aren't only interested in Lipitor advertising. In the wake of the release of Enhance trial data, the duo sent letters to Merck and Schering-Plough vowing an investigation and making clear that DTC ads for the drug would be a major focus.

“Given the frequency of Vytorin advertisements, it concerns us that a study showing that Vytorin provides no increased benefit was not issued for nearly two years while (DTC ads) were carried on the airwaves,” they wrote. “This situation raises concerns that the drug companies and their advertisement agencies profited at the significant expense of patients' health.” 
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.